Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ESPORTS ENTERTAINMENT GROUP, INC.ex991.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  March 3, 2011

DK SINOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada
 
333-156302
 
26-3062752
(State or Other Jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
     
Identification No.)

Dongxing Building, 4th Floor
No.1 Xinke Road,
Xi’an, the People’s Republic of China 710043
(Address of Principal Executive Offices)
 
86-29-8224-7500
(Registrant's telephone number, including area code)

  Not Applicable.
(Former name or former address, if changed since last report)
 
 
Copies to:
 
Marc J. Ross, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor,
New York, NY 10006
Tel: (212) 930 9700
Fax: (212) 930 9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




 
 

 
 
Item 8.01.     Other Events


On March 3, 2011, the Company issued a press release annexed hereto as Exhibit 99.1 hereto.
 
Item 9.01      Financial Statements and Exhibits.
 
(d) Exhibits.
 
 
99.1
Press release dated March 3, 2011, issued by DK Sinopharma, Inc.
     

 
 

 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: March 10, 2011
   
 
DK SINOPHARMA, INC.
     
 
By:  
/s/ Dongke Zhao
 
Dongke Zhao
 
Chief Executive Officer